Robert Hollingsworth BA, PhD

Dr. Bob Hollingsworth is Director of Cancer Biology at MedImmune, the biologics subsidiary of AstraZeneca. He oversees preclinical research ranging from target identification to in vivo lead testing, including development of new antibody-drug conjugates for cancer therapy. Prior to joining MedImmune, Dr. Hollingsworth served as a Director at GlaxoSmithKline for eleven years, working in the oncology, virology, and genomics research. He has been involved in numerous important oncology research discoveries, including early insights into the role of the microenvironment in tumorigenesis, the function of tumor suppressor proteins, cell cycle control, and the identification of biomarkers for cancer. He has also contributed to the development of several cancer drugs, including lapatinib (Tykerb). He brings experience in both small molecule and biologics drug discovery to the ADC field.